YIH
BCAX

Y-Intercept (HK)’s Bicara Therapeutics BCAX Stock Holding History

Y-Intercept (HK)’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-59,937
Closed -$1.01M – 2143
2025
Q4 		$1.01M Buy
+59,937
New +$1.02M 0.02% 979

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Y-Intercept (HK)'s BCAX Position: Q1 2026 in Review

Y-Intercept (HK) sold out of Bicara Therapeutics (BCAX) in Q1 2026, closing a stake of 59,937 shares — an estimated $1.01M sold.

Y-Intercept (HK) first reported a position in BCAX in Q4 2025 and held it in 1 quarter. The position peaked at $1.01M in Q4 2025. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Y-Intercept (HK) reported no remaining Bicara Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Y-Intercept (HK) sold 59,937 Bicara Therapeutics shares in Q1 2026, an estimated $1.01M.
  • Y-Intercept (HK) first reported a position in Bicara Therapeutics in Q4 2025 and held it in 1 quarter.
  • Y-Intercept (HK)'s Bicara Therapeutics position peaked at $1.01M in Q4 2025.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Y-Intercept (HK)'s 13F filing for Q1 2026, filed 27 Apr 2026.